HCV and Diabetes: Towards a ‘Sustained’ Glycaemic Improvement After Treatment With DAAs?

Clinical Microbiology and Infection - United Kingdom
doi 10.1016/j.cmi.2016.09.021
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

HCV and Diabetes: Towards a ‘Sustained’ Glycaemic Improvement After Treatment With DAAs? – Authors' Reply

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2017English

Efficacy and Tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected Patients With Psychiatric Disorders

BMC Infectious Diseases
Infectious Diseases
2020English

Significant Improvement of Glycaemic Control in Diabetic Patients With HCV Infection Responding to Direct-Acting Antiviral Agents

Journal of Medical Virology
VirologyInfectious Diseases
2017English

Systemic Adipokines, Hepatokines and Interleukin-6 in HCV-monoinfected and HCV/HIV Coinfected Patients Treated With Direct Antiviral Agents (DAAs)

Clinics and Research in Hepatology and Gastroenterology
HepatologyGastroenterology
2018English

The “Real-World” Efficacy and Safety of DAAs for the Treatment of HCV Patients Throughout Japan

Journal of Gastroenterology
Gastroenterology
2018English

Treatment of Periodontal Disease for Glycaemic Control in People With Diabetes

2010English

DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk During Anti-HCV Treatment

PLoS ONE
Multidisciplinary
2016English

HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Gastroenterology
HepatologyGastroenterology
2019English

Enhancing MIDAS Towards a Transparent Interoperability Between SaaS and DaaS

2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy